Interesting Article from MDLinx

draurelromila1@gmail.com has forwarded you an article from MDLinx Psychiatry , part of the MDLinx network MDLinx  Psychiatry 5 minutes to stay current Your Article Summary Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis Neuropsychiatric Disease and Treatment, 06/20/12 Ye W et al. – Consistent with prior global research, this retrospective naturalistic study of schizophrenia outpatients in Japan found that olanzapine is more likely to be used as monotherapy and to be used as monotherapy for a longer duration than risperidone. Methods Outpatients diagnosed with schizophrenia in the Japan Medical Data Center database were identified using International Statistical Classification of Diseases and Related Health Problems, 10th Revision, diagnosis codes. Patients were between 20 and 65 years old, initiated on olanzapine or risperidone therapy between August 2003 and July 2008, and continuously enrolled during the 6 months prior to and the 12 months following the initiation date. Antipsychotic polypharmacy was defined as concurrent use of two or more antipsychotics. The probability of monotherapy during the 12-month follow-up period was assessed using a propensity score-adjusted generalized estimating equation model. Duration of monotherapy was contrasted using a propensity score-adjusted bootstrapping model. Results After applying all inclusion and exclusion criteria, the final analytic sample consisted of 332 olanzapine- and 496 risperidone-treated outpatients. At treatment initiation, 61.5% of the olanzapine-treated patients and 45.6% of the risperidone-treated patients received antipsychotic monotherapy (P < 0.001). After correcting for background differences, monotherapy was more common among olanzapine-treated patients (P = 0.001). In addition, olanzapine was used as monotherapy for a longer duration (P = 0.006). Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties. Other articles in Psychiatry >> Click here to see the complete list Atypical Antipsychotic Drugs, Schizophrenia, and Metabolic Syndrome in Non-Euro-American Societies Clinical Neuropharmacology, 05/22/12 Role of aripiprazole in treatment-resistant schizophrenia Neuropsychiatric Disease and Treatment, 06/05/12 Update on the development of lurasidone as a treatment for patients with acute schizophrenia Drug Design, Development and Therapy, 05/23/12 ©1999-2012 MDLinx, Inc. This email was sent at the request of draurelromila1@gmail.com. Copyright ©2012 M3 USA. All Rights Reserved. M3 USA considers the privacy of its users to be of utmost importance and works to protect it. We will not sell or share your information with 3rd parties without your permission. For comprehensive information about the steps that M3 USA takes to respect your privacy, please read our Privacy Policy. This email has been sent by MDLinx, a division of M3 USA, 1215 17th St NW Washington, DC 20036 Tel: +1.202.293.2288 Fax: +1.202.293.1690